• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Glenmark Pharmaceuticals Ltd.
    10 Jun 2025
    2116.30
    3.14%
    Glenmark Pharma rises 2% as company to launch blood cancer treatment drug
    Business Standard
    Glenmark Pharma shares gained 2 per cent in trade as company announced the upcoming launch of zanubrutinib, under the brand name Brukinsa in India
    Copy LinkShare onShare on Share on Share on
    Glenmark Pharmaceuticals Ltd. has gained 33.08% in the last 3 Months
    logo
    Dr. Reddy's Laboratories Ltd.
    07 Jun 2025
    US FDA Observation
    1291.30
    3.25%
    Dr. Reddy's Laboratories: Holding on to a sweet promise
    Business Line
    The transition from Revlimid led growth to diabetes portfolio will be rocky yet rewarding
    Copy LinkShare onShare on Share on Share on
    Dr. Reddy's Laboratories Ltd.'s price crossed above 50Day SMA today
    logo
    Wockhardt Ltd.
    05 Jun 2025
    1493.70
    2.27%
    Wockhardt's New Antibiotic Zaynich Targets $7-Billion US, Europe Market
    Wockhardt's New Antibiotic Zaynich Targets $7-Billion US, Europe Market
    NDTV Profit
    The company plans to file for USFDA approval in the second quarter of the current financial year.
    Copy LinkShare onShare on Share on Share on
    Wockhardt Ltd. has an average target of 1870.00 from 1 broker.
    Wockhardt files for regulatory approval of novel antibiotic Zaynich
    Business Line | 05 Jun 2025
    logo
    Dr. Reddy's Laboratories Ltd.
    05 Jun 2025
    US FDA Observation
    1291.30
    3.25%
    Alvotech, Dr Reddy's ink pact to co-develop Biosimilar for cancer treatment
    Business Line
    Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.
    Dr Reddy's, Alvotech to co-develop biosimilar of cancer drug Keytruda
    Business Standard | 05 Jun 2025 4 more
    Dr Reddy's, Alvotech Partner To Develop Biosimilar For Cancer Treatment
    NDTV Profit | 05 Jun 2025
    Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment
    Business Standard | 05 Jun 2025
    Alvotech, Dr Reddy's partner to develop Keytruda Biosimilar
    Business Line | 05 Jun 2025
    Dr Reddy's Labs rallies 4%, hits over four-month high; here's why
    Business Standard | 05 Jun 2025
    logo
    Glenmark Pharmaceuticals Ltd.
    05 Jun 2025
    2116.30
    3.14%
    Stocks to buy today, June 5: Glenmark Pharma, M&M among analyst top picks
    Business Standard
    Stocks to buy today, June 5: Analyst at Religare Broking has recommended buying Glenmark Pharma, M&M and one more stock with upside potential
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 404 to 396 in Jun 2025 qtr
    logo
    Ipca Laboratories Ltd.
    04 Jun 2025
    1320.10
    -0.02%
    Broker's call: Ipca Lab (Add)
    Business Line
    InCred Equities
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 294 to 270 in Jun 2025 qtr
    logo
    Gland Pharma Ltd.
    04 Jun 2025
    1921.00
    2.28%
    USFDA clears Gland Pharma's generic Angiotensin II injection
    Business Line
    The drug is used to raise blood pressure in adults with septic or other distributive shock.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 203 to 212 in Jun 2025 qtr.
    Gland Pharma share rises 2% in trade on Wednesday, June 4; here's why
    Business Standard | 04 Jun 2025
    logo
    Sun Pharmaceutical Industries Ltd.
    04 Jun 2025
    1591.70
    0.68%
    Modest setback for Sun Pharma, 18% fall in SPARC shares as drug fails to deliver
    Business Line
    SPARC, the R&D arm of Sun Pharma, was testing SCD-044 for two auto-immune indications in a Phase-2 trial. Though the study did not show any safety concerns, the drug failed the endpoint of a 75 per cent improvement in PASI score and EASI score at week 16
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical Industries Ltd. is trading below all available SMAs
    Sun Pharma Advanced Research shares tank 20% after psoriasis drug fails Phase 2 trials
    Economic Times | 04 Jun 2025 4 more
    Sun Pharma Advanced Research Shares Fall To Nearly One-Month Low On Discontinuing Psoriasis Drug
    NDTV Profit | 04 Jun 2025
    Sun Pharma Advanced Research shares fell 15%; What's rattling investors?
    Business Standard | 04 Jun 2025
    Sun Pharma discontinues 2 trials of drug candidate for not meeting primary endpoints
    Business Line | 03 Jun 2025
    Sun Pharma halts development of SCD-044 drug after trial disappointment
    Business Standard | 03 Jun 2025
    logo
    Sun Pharma Advanced Research Company Ltd.
    04 Jun 2025
    141.58
    0.35%
    SPARC shares fall 18% as drug candidate gets discontinued
    Business Line
    At 12.26 pm on Wednesday, SPARC shares were at down -18.25 per cent at 159.90
    Copy LinkShare onShare on Share on Share on
    Sun Pharma Advanced Research Company Ltd. has lost -37.28% in the last 1 Year
    logo
    Wockhardt Ltd.
    04 Jun 2025
    1493.70
    2.27%
    Wockhardt Aims To Regain Rs 5,000-Crore Revenue In Three Years, Says Chairperson Khorakiwala
    Wockhardt Aims To Regain Rs 5,000-Crore Revenue In Three Years, Says Chairperson Khorakiwala
    NDTV Profit
    In FY25, the company's revenue stood at Rs 3,012 crore, compared to Rs 2,798 crore in FY24.
    Copy LinkShare onShare on Share on Share on
    Wockhardt Ltd. is trading above its 200 day SMA of 1461.0
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd